Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dolutegravir/rilpivirine - Janssen/ViiV Healthcare

Drug Profile

Dolutegravir/rilpivirine - Janssen/ViiV Healthcare

Alternative Names: Dolutegravir sodium/rilpivirine hydrochloride; Juluca; Rilpivirine hydrochloride/dolutegravir sodium; Rilpivirine/dolutegravir

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development; ViiV Healthcare
  • Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Benzonitrile; Nitriles; Oxazines; Pyrimidines; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 30 May 2023 ViiV Healthcare completes the phase III SWORD-1 trial for HIV infections (Treatment-experienced) in USA, Argentina, Australia, Belgium, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, Taiwan, the UK (PO) (NCT02429791)
  • 25 May 2023 ViiV Healthcare completes the phase III SWORD-2 trial for HIV infections (Treatment-experienced) in the US, the UK, Argentina, Taiwan, Australia, Canada, France, Germany, Italy, Russia, and Spain (PO) (NCT reference) (NCT02422797)
  • 06 Jan 2023 ViiV Healthcare in a collaboration with Janssen Research & Development plans a phase I/II trial in HIV-1 infections (Treatment-experienced, In children) in February 2023 (NCT05674656)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top